One Scaffold, Three Binding Modes: Novel and Selective Pteridine Reductase 1 Inhibitors Derived from Fragment Hits Discovered by Virtual Screening† by Mpamhanga, Chidochangu P. et al.
pubs.acs.org/jmc Published on Web 06/15/2009 r2009 American Chemical Society
4454 J. Med. Chem. 2009, 52, 4454–4465
DOI: 10.1021/jm900414x
OneScaffold,ThreeBindingModes:NovelandSelectivePteridineReductase1InhibitorsDerivedfrom
Fragment Hits Discovered by Virtual Screening
†
Chidochangu P. Mpamhanga, Daniel Spinks, Lindsay B. Tulloch, Emma J. Shanks, David A. Robinson, Iain T. Collie,
Alan H. Fairlamb, Paul G. Wyatt, Julie A. Frearson, William N. Hunter, Ian H. Gilbert, and Ruth Brenk*
Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, U.K.
Received March 31, 2009
The enzyme pteridine reductase 1 (PTR1) is a potential target for new compounds to treat human
African trypanosomiasis. A virtual screening campaign for fragments inhibiting PTR1 was carried out.
Two novel chemical series were identified containing aminobenzothiazole and aminobenzimidazole
scaffolds, respectively. One of the hits (2-amino-6-chloro-benzimidazole) was subjected to crystal
structure analysis and a high resolution crystal structure in complex with PTR1 was obtained,
confirming the predicted binding mode. However, the crystal structures of two analogues (2-amino-
benzimidazole and 1-(3,4-dichloro-benzyl)-2-amino-benzimidazole) in complex with PTR1 revealed
two alternative binding modes. In these complexes, previously unobserved protein movements and
water-mediated protein-ligandcontacts occurred, which prohibited acorrect prediction of the binding
modes.Onthebasisofthealternativebindingmodeof1-(3,4-dichloro-benzyl)-2-amino-benzimidazole,
derivatives were designed and selective PTR1 inhibitors with low nanomolar potency and favorable
physicochemical properties were obtained.
Introduction
Human African trypanosomiasis (HAT
a), or sleeping sick-
ness, claims the lives of at least 48000 people every year, and
about 60 million people in sub-Saharan Africa are at risk of
infection.
1HAT,transmittedbythetsetsefly,iscausedbytwo
subspecies of the protozoan parasite Trypanosoma brucei.
2,3
The disease progresses in two stages. In the first stage, the
parasites proliferate solely within the bloodstream and extra-
cellular tissue space. In the late stage, the central nervous
system (CNS) becomes infected, causing symptoms that are
characteristic of the disease. If left untreated, HAT is always
fatal. Current treatment is hampered by expensive and toxic
drugs and emerging resistance and treatment failures compli-
cate the treatment even further.
1 Accordingly, there is an
urgent need for the development of safer and more efficient
drugs.
Promising targets for new therapeutics are enzymes in-
volved in pterin and folate metabolism.
4 Both pterins and
folates are essential for growth in Leishmania ssp. and related
trypanosomatids, yet genes encoding enzymes for de novo
synthesis are lacking from their respective genomes.
5 There-
fore, trypanosomatids are required to salvage oxidized pter-
idinessuchasbiopterinandfolateandtosubsequentlyreduce
them to active cofactors such as tetrahydrobiopterin (H4B)
and tetrahydrofolate (H4F) by means of pteridine reductase
1 (PTR1; EC 1.5.1.33) and the bifunctional enzyme dihydro-
folatereductase-thymidylatesynthase(DHFR-TS;EC1.5.1.4
and 2.1.1.45, respectively).
4
DHFR is a well established drug target for a range of
diseases.
6,7 It is therefore surprising that antifolates com-
monly used as anticancer or anti-infective drugs have not
shown equivalent efficacy against T. brucei or the related
organism L. major.
8,9 However, for the latter organism, in
whichthismetabolismhasbeenmoreextensivelyinvestigated,
it has been demonstrated that PTR1 not only reduces its
principlesubstratesbiopterinanddihydrobiopterin(H2B)but
also dihydrofolate (H2F) and thus circumvents DHFR in-
hibition.
8,10 It is therefore possible that DHFR and PTR1
have to be inhibited cooperatively in order to a produce a
therapeutic effect in L. major.
Recent evidence indicates that PTR1 might also be a
T. brucei drug target in its own right. Unlike L. major ptr1
-
mutants,
8,11 the bloodstream form of T. brucei ptr1
- mutants
isnolongerviableinculturemedium,suggestingthatPTR1is
essential for parasite survival (Sienkiewicz and Fairlamb,
unpublished results). This observation prompted us to design
TbPTR1 inhibitors to support chemical validation of this
potential target andtoserveasleadsfor furtherdevelopment.
Several PTR1 inhibitors are known. Most of them are
derived from DHFR inhibitors and contain either a 2,4-
diaminopteridine, 2,4-diaminoquinazoline, or 2,4-diamino-
pyrimidinecore(Figure1).
6,7,12,13Itisthereforenotsurprising
that many PTR1 inhibitors also inhibit human and T. brucei
DHFR with inhibition constants in the low micromolar to
nanomolar range.
12,13 This broad spectrum activity is unde-
sirable both for chemical tools and lead compounds: first,
effects due to PTR1 inhibition cannot be distinguished from
those due to TbDHFR inhibition and, second, inhibition of
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hDHFR will probably lead to undesirable side effects. More-
over, thesecorestructures have a relatively highpolarsurface
area(PSA),rangingfrom77A ˚ 2toover100A ˚ 2.Thesetypesof
compoundsare thereforelesssuitablestartingpointsfor drug
design, particularly when CNS active drugs are required to
treat the second stage of the disease.
14
Crystal structures of LmPTR1 and TbPTR1 have been
determined.
15,16 The substrate binding site is a well-defined
cleft (Figure 2). In the majority of the crystal structures, the
aromaticheterocycleoftheligandsissandwichedbetweenthe
nicotinamide part of the cofactor NADP
+ and the aromatic
moiety of Phe97 (T. brucei numbering). Further, the ligands
form extensive hydrogen bonds with the cofactor and sur-
rounding amino acids. Even relatively small compounds
such as 6-methylpteridine-2,4-diamine (Figure 1) are potent
LmPTR1 inhibitors with inhibition constants in the low
micromolar range.
13 Collectively, these data suggest that the
PTR1 binding pocket is well suited for a fragment-based
strategy for hit discovery.
In fragment-based hit discovery, libraries are screened that
typically contain molecules with a molecular mass less than
300 Da and with less than three hydrogen-bond donors and
six hydrogen-bond acceptors.
17,18 These constraints support
theidentificationofsmallligandsthatbind witha highligand
efficiency and that can be readily optimized to potent drug-
like inhibitors. Usually, biophysical methods such as X-ray
crystallography, nuclear magnetic resonance (NMR), or sur-
face plasmon resonance (SPR) are used to detect the initial
hits, which often have binding affinities in the low millimolar
to low micromolar range. In a few cases, also computational
methods have been applied to predict fragment binding.
17
Here,wedescribeoureffortstosupportchemicalvalidation
of TbPTR1 as a drug target. We report on the discovery of
novel TbPTR1 inhibitors using computational fragment
screening. The implications of this study for PTR1 inhibitor
design and virtual fragment screening are discussed.
Results
Virtual Screening. The following strategy was adopted for
virtual screening: (1) selection of an appropriate TbPTR1
structure as template for docking; (2) compilation of a
fragment library; (3) docking of the fragment library into
the active site of the crystal structure; (4) selection of hits
using a combination of pharmacophore-filtering and visual
inspection.
Superposition of the available TbPTR1 crystal structures
revealedthatthebindingsiteisratherrigid,andtheobserved
movements are within the crystallographic coordinate error
(Figure 2). The choice of crystal structure should therefore
notsignificantlyinfluencethedockingresults,andthecrystal
structure of TbPTR1 in complex with triamterene and
NADP
+ (PDB code 3BME) was used as template for virtual
screening.
With one exception, in all available TbPTR1 crystal
structures, the ligands form a similar hydrogen-bonding
network as observed in the methotrexate and triamterene
complexes (Figure 2). However, if in a pharmacophore
hypothesis all hydrogen bonds were required, only com-
pounds resembling the known inhibitors and hence with
the same problematic physicochemical properties would
be retrieved. Therefore, the pharmacophore criteria were
relaxed to tolerate all compounds that can interact with the
β-phosphate group of the cofactor and can form any of the
additional hydrogen bonds.
Recently, we reported on the assembly of a database
containing commercially available lead-like compounds.
19
To obtain a library of fragment-like compounds, this lead-
like set was further filtered for compounds containing fewer
than 20 heavy atoms, only one or two ring systems, at least
one hydrogen-bond donor group, fewer than four rotatable
bonds,andaClogP/ClogDoflessthan3.5.Byapplyingthese
filters, the initial set containing more than 250000 molecules
was reduced by approximately 90%.
The resulting fragment library was sequentially docked
into the TbPTR1 binding site using DOCK 3.5.54
20,21 A
binding mode was generated for 25386 of the 26084 com-
pounds contained in the set. Subsequent filtering of the
predicted orientations with the pharmacophore hypothesis
described above resulted in 2725 compounds. Compounds
containing known PTR1 inhibitor scaffolds (Figure 1) were
removed, and the remaining compounds were grouped into
five different clusters based on which of the hydrogen bond-
ing interactions previously observed in PTR1-ligand com-
plexes (Figure 2) they fulfilled. The clusters were visually
inspected in order to identify compounds representing a
diverse set of scaffolds. In addition, the PSA for the scaffold
involved in forming the key hydrogen bonds should ideally
be less than 70 A ˚ 2. The selected compounds were subse-
quently minimized in the binding site while keeping the
protein rigid. The criteria for compound purchase were
quality of the hydrogen-bond network after minimization
and shape complementarity of the ligand and the binding
site. Finally, 59 compounds were selected for testing, out of
which 45 compounds were available for purchase (Table S1,
Supporting Information).
Figure 1. CommoncorestructuresofPTR1andDHFRinhibitors.
Figure 2. LigandsandbindingsiteresiduesofTbPTR1-methotrex-
ate complex (2C7V, blue carbon atoms) superimposed with those
from the triamterene complex (green carbon atoms).4456 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 14 Mpamhanga et al.
Hit Evaluation. PTR1 inhibition was measured using a
novel assay platform recently developed by our group, de-
tails of which will be reported in a separate publication.
Given the low molecular weight of the screening hits, inhibi-
tion was initially tested at 100 μM. Three fragments repre-
senting three different chemical scaffolds demonstrated
more than 50% inhibition and a further seven compounds
from three additional series showed between 30 and 50%
inhibition (Table S1, Supporting Information). The hit
compounds from the two most potent series of this initial
testing containing aminobenzothiazole or aminobenzimida-
zole cores were further evaluated.
Aminobenzothiazole Series. For the aminobenzothiazole
series, three compounds were selected for purchase (1-3,
Table 1), but only two were available (2 and 3). They have
apparent Ki (Ki
app) values of around 21 and 141 μM, giving
ligand efficiencies
22 of 0.46 and 0.29 kcal mol
-1/heavy
atom, respectively. The PSA of their core scaffold is 39 A ˚ 2
(60-65A ˚ 2forthewholemolecule),whichis38to61A ˚ 2lower
than that of the previously known PTR1 inhibitor cores
(Figure 1). The pairwise Tanimoto coefficients between
previously known PTR1 and DHFR inhibitors scaffolds
and these compounds are only 0.1-0.2.
AllattemptstococrystallizetheseligandswithPTR1orto
soakthemintocrystals wereunsuccessful.Thisismost likely
due to the limited solubility of these compounds. In the
proposed binding mode, the ligand is sandwiched between
the aromatic moiety of Phe97 and the nicotinamide part of
NADP
+. Further, the ligand forms one hydrogen bond with
Ser95 and two with the cofactor (Figure 3).
Aminobenzimidazole Series. In the first instance, only one
compound containing an aminobenzimidazole scaffold was
purchased (4, Table 1). This is the most potent compound
discovered from this virtual fragment screen, with a Ki
app value
of 10.6 μM and a ligand efficiency of 0.62 kcal mol
-1/heavy
atom. The compound has a low PSA of 55 A ˚ 2 and Tanimoto
coefficients of 0.3-0.5 when compared with previously known
PTR1 and DHFR inhibitor scaffolds.
In the proposed binding mode, the ligand is protonated at
the nitrogen atom facing the phosphate group of NADP
+
and forms hydrogen bonds with Ser95 and the cofactor
(Figure 4b). To initially validate this binding mode in the
absence of a crystal structure, close analogues were tested
with variations in the six position (5 and 6) and on N1 (7-9,
Table 2). Removing the chloro-substituent (5) was accom-
panied by a more than 20-fold drop in affinity, whereas
replacing this substituent with a methylphenyl group
(6) resulted in an equipotent compound. Consistent with
the proposed binding mode addition of an ethyl group in
the N1 (7) position diminished affinity, as this substituent
Table 1. Docking Results, PTR1 Inhibition Data, and PSA of Virtual Screening Hits
b
aThe cores of compounds 1-3 were defined as 2-aminobenzothiazole and of compound 4 as 2-aminobenzimidazole.
bKi
app and Hill slopes are
averaged over at least two independent measurements.
Figure 3. Modeled binding mode of 2. The ligands is sandwiched
between the aromatic moiety of Phe97 and the nicotinamide part of
NADP
+. Further, theligand forms hydrogen bonds with Ser95and
the cofactor.Article Journal of Medicinal Chemistry, 2009, Vol. 52, No. 14 4457
prevents hydrogen-bonding interaction with the phosphate
group of NADP
+. In contrast, larger substituents on this
position restored affinity (8) or even led to more than a
20-fold increase in affinity (9) compared to the virtual
screening hit.
The binding modes of 4, 5, and 9 were determined using
X-ray crystallography (Table 3). Ligand 4 adopts two dis-
tinct binding modes with either the N1 or N3 being proto-
nated and forming a hydrogen bond with the phosphate
group of the cofactor (Figure 4a). The ratio of these binding
modes is 70:30 as estimated by crystallographic B factors. In
themajorconformationthechloro-substituentpacksagainst
a hydrophobic surface formed by Leu209 and Pro210,
whereas in the minor conformation, the chloro atom sits in
the open cavity of the active site and forms no van der Waals
contacts. The major binding mode resembles closely the best
scoring binding mode of this ligand predicted by DOCK
3.5 (rmsd=0.95 A ˚ , Figure 4b). The tautomeric form of
4 required in the minor binding mode was present in the
docking database but not stored in the final hit list because
onlythehighestscoringversionofeachcompoundwaskept.
The predicted binding mode of this tautomer is within one A ˚
rmsd of the crystallographically determined minor binding
mode of 4 (data not shown).
For the unsubstituted fragment 5 only one binding mode
was detected (Figure 5). In this binding mode, the ligand
forms an edge-face interaction with Trp221 and water
mediated hydrogen bonds with the cofactor. The water
molecule interacting with the R-phosphate group of the
cofactor occupies a similar position as a water molecule in
a LmPTR1 ligand complex determined previously.
23 The
other water molecule has not been observed in any of the
previously published structures. Structural water molecules
were not considered in the docking protocol and binding
mode prediction of 5 failed (rmsd=3.04 A ˚ ).
The most potent ligand 9 adopts a binding mode, which
does not resemble any previously observed binding mode
(Figure 6). This ligand binds in an area of the active site
perpendicular to the canonical binding mode, 3.7 A ˚ away
from the nicotinamide moiety of the cofactor. The core
occupiesa pocket formed by Phe97, Asp161, Met163, Cys168,
Phe171, Tyr174, and Gly205. The ligand forms a bidentate
interaction with the carboxyl group of Asp161 via the proto-
nated N3 and the 2-amino group, which also hydrogen bonds
to the backbone carbonyl of Gly205. The dichloro-phenyl
moiety is placed in a pocket defined by the side chains of
Val206, Trp221, Leu263, Cys168, and Met163. The pocket is
closed by the C-terminal residues His267 and Asp268 from a
neighboring subunit. The ligand does not form any hydrogen
bonds with the cofactor. The phosphate group of NADP
+ is
surrounded by water molecules, which occupy similar posi-
tions as in PTR135 (Figure 5).
In one monomer (chain D) of the PTR39 complex, an
additional molecule of 9 was observed in the substrate
binding site at lower occupancy. In this binding mode the
dichloro-phenyl moiety of the ligand is sandwiched between
the nicotinamide part of the cofactor and Phe97 while the
benzimidazole part is hydrogen-bonded to the phosphate
groups of the cofactor displacing a near-by loop (Leu208-
Ala212).Thismoleculewasonlymodeledwithanoccupancy
of 0.75. The largely hydrophobic nature of the interactions
formed within the substrate binding site coupled with the
conformational change required for binding suggests that
the binding mode can be disregarded as a crystallographic
artifact.
Despite the 1-substituted analogue occupying a very
different area of the active site in PTR1 in its main binding
mode, the overall rmsd between the main chain atoms of
the TbPTR134 and TbPTR139 complexes is only 0.25 A ˚
(calculated for chain A), indicating that there is negligible
gross conformational change. Considering residues within
theactive siteregionthermsdis0.43A ˚ formainchainatoms
and 0.65 A ˚ for all atoms, respectively, reflecting the limited
nature of ligand induced conformational change. However,
the torsion angle defined by CA-CB-CD-CD2 of Trp221
changes from -65  to -75  (Figure 6). Without this change,
the dichloro moiety of 9 would clash with the tryptophan
side chain. In addition, the sulfur atom of Cys168 is shifted
by 2 A ˚ in order to accommodate the aminobenzimidazole
moiety.
Figure 4. (a) View in the binding site of PTR134 together with
Fo-Fc omit map (contoured on 2.0σ), which was calculated by
omitting the ligand from the final model. The ligand adopts two
distinct binding modes. In the major confirmation (green carbon
atoms), the chloro-substituent packs against Leu209 and Pro210,
whereas in the minor conformation (yellow carbon atoms), the
chloro atom sits in the open cavity of the active site. (b) Modeled
binding mode of 4 (orange carbon atoms) superimposed with the
dominant binding mode determined crystallographically (green
carbon atoms).4458 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 14 Mpamhanga et al.
Receptor flexibility was not considered during docking and
the docking program was set up to place a ring system close to
the phosphate group of the core factor. As a result, a low
scoring binding mode was obtained for 9, which was incon-
sistent with the above-described pharmacophore hypothesis
and which did not resemble the experimentally detected one.
All attempts to determine the binding mode of 6 failed,
probably due to the limited solubility of this compound.
Most likely 6 adopts a similar binding mode as 4 with the
methylphenyl substituent located in the same area of the
binding site as the chloro-substituent of the screening hits.
Adopting one of the alternative binding modes would either
lead to a steric clash of the aromatic substituent with Trp221
or Phe171.
In summary, depending on the substituents the amino-
benzimidazole core adopts three distinct binding modes in
the PTR1 active site (Figure 7). Only one of them (4)
resembles thepreviouslyobservedbindingmodes(Figure2).
Hit Expansion of Aminobenzimidazole Series. Crystal
structure analysis of TbPTR139 revealed two hydrophobic
Table 3. Crystallographic Data and Refinement Statistics of TbPTR1-Ligand Complexes
a
ligand complex 45 9 1 2
Details of Data Collection
PDB code 2WD7 3GN1 3GN2 2WD8
space group P21 P21 P21 P21
unit cell dimensions (A ˚ ) a = 74.68 a = 74.64 a = 74.89 a = 74.66
b = 89.89 b = 90.41 b = 90.78 b = 89.89
c = 82.70 c = 82.64 c = 82.86 c = 83.05
β = 115.48 β = 115.73 β = 115.85 β = 115.54
resolution range (A ˚ ) 30.0-1.90 30.66-2.00 67.42-1.60 30.0-2.10
(2.0-1.90) (2.10-2.00) (1.69-1.60) (2.18-2.10)
observations 147241 341528 522950 118137
unique observations 71041 63246 124512 48991
redundancy 2.1 5.4 4.2 2.4
completeness (%) 91.6 (63.8) 94.8 (89.9) 94.9 (93.7) 84.7 (84.9)
ÆI/σ(I)æ 13.0 (2.4) 9.3 (5.1) 8.3 (2.0) 11.5 (2.43)
Rmerge
b (%) 5.4 (31.1) 5.1 (13.6) 6.7 (35.9) 9.4 (56.9)
Refinement Statistics
resolution range (A ˚ ) 30.0-1.9 30.66-2.00 67.42-1.60 30.0-2.10
R factor
c %( Rwork/Rfree) 15.5/20.2 15.5/21.6 14.6/17.8 15.8/22.6
number of atoms
d 7545/195/88/687 7480/192/20/896 7568/192/95/1272 7453/144/100/733
mean B factor
e (A ˚ 2) 26/21/27/35 12/9/26/21 11/8/11/27 30/30/28/41
rms bond length deviation (A ˚ ) 0.016 0.014 0.009 0.012
rms bond angle deviation (deg) 1.627 1.473 1.293 1.419
aValuesbetweenbracketsareforthehighestresolutionshell.
bRmerge=
P
|I-ÆIæ|/
P
ÆIæ.
cRfactor=
P
Fo-Fc|/
P
Fo.
dNumberofatomsofprotein,
cofactor, ligand, and water molecules, respectively.
eMean B factor for protein, cofactor, ligand, and water molecules, respectively
Table 2. PTR1 Inhibition Data of Readily Available Analogues of 2-
Amino-6-chloro-benzimidazole (4)
a
aKi
app and Hill slopes are averaged over at least two independent
measurements.
Figure 5. Crystallographically determined binding mode of 5 to-
gether with Fo-Fc omit map (contoured on 2.0σ), which was
calculated by omitting the ligand from the final model. Two water
molecules mediate contacts between the phosphate groups of the
cofactor and the ligand.Article Journal of Medicinal Chemistry, 2009, Vol. 52, No. 14 4459
pockets filled with structural water molecules next to the
aminobenzimidazole core of 9: a larger pocket toward
Trp221 and a smaller pocket bordered by Pro167, Tyr174,
and Asn175 (Figure 8). To improve affinity of the screening
hits,derivativeswithmoietiessuitabletofillthelargerpocket
were designed (Table 4). The 7-chloro-derivative 10 has a Ki
app
of 0.5 μM and is equipotent to 9. Substituting the chloro-atom
with a propoxy-group (11) led to a 10-fold increase in potency
resulting in a Ki
app of 0.05 μM. Introducing a phenyl group in
thispositionafforded12.WithaKi
appof7nMthiswasthemost
potent compound in the series.
The crystal structure of TbPTR1312 confirmed the mod-
eled binding mode (Table 3, Figure 9). As predicted, the
Figure 6. Crystallographically determined binding mode of 9 (or-
ange carbon atoms for ligand and blue carbon atoms for protein)
superimposed with the receptor conformation used for docking
calculations (gray carbon atoms) together with Fo-Fc omit map
(contoured on 2.0σ), which was calculated by omitting the ligand
from the final model. To accommodate the ligand in the binding
site, the side chain of Trp221 rotated by 10  and the sulfur atom of
Cys168 shifted by 2 A ˚ .
Figure 7. Superposition of the crystallographically determined
binding modes of 4 (orange carbon atoms), 5 (green carbon
atoms),and9(graycarbonatoms).Dependingonthesubstituents,
the amino-benzimidazole core adopts three different binding
modes.
Figure 8. Cut-away view of solvent accessible surface of the bind-
ing pocket of PTR139. Two hydrophobic pockets filled with
ordered water molecules are close the aminobenzimidazole core of
9, a smaller pocket bordered by Pro167, Tyr174, and Asn175, and a
larger one toward Trp221.
Table 4. Hit Expansion of the Aminobenzimidazole Series
a
aKi
app and Hill slopes are averaged over at least two independent
measurements.4460 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 14 Mpamhanga et al.
inhibitorbindsinasimilarmannerastheparentcompound9
(Figure 6). The additional phenyl ring lies between the
side chains of Phe97 and Trp221, forming and edge-face
interaction with the latter residue and displacing the struc-
tural water molecules, which were found in this area in
TbPTR139.
All compounds showed no significant inhibition of
T. brucei or human DHFR when tested at concentrations
ofupto30μMwhentheirKi
appvalueswerebelow1μMand
up to 500 μM for all other compounds. The most potent
inhibitor 12 has favorable physicochemical properties
for cell and CNS penetration with a molecular weight of
368 Da, a PSA of 55 A ˚ , and an experimentally determined
logDof3.7units. However, whencompound12was assayed
against T. brucei in cell culture, the EC50 value obtained was
only 10 μM, despite the compound having a Ki
app of 7 nM
against PTR1.
Discussion
T. brucei PTR1 has recently been genetically validated as a
drugtargetforHAT(SienkiewiczandFairlamb,unpublished
results). Here, we were interested in developing inhibitors of
theenzymetofacilitatechemicalvalidationofPTR1asadrug
target for HAT and also to provide drug leads. The leads
should have suitable physicochemical properties for further
optimization; in the case of stage two HAT, this includes
being able to penetrate the CNS.
2,3 One property that is
generally needed for such molecules is a low polar surface
area(<70A ˚ 2).
14PublishedinhibitorsofPTR1sufferfromlow
solubility and a relatively high PSA, which reduces the
possibility of blood-brain barrier permeation. Furthermore,
known PTR1inhibitorsalso often inhibitDHFR,which may
give risetotoxicity.
12,13 Therefore we aimed to discover novel
scaffolds with a low PSA and that inhibit PTR1 and are
selectiveoverDHFR.Toachievethesegoals,weusedavirtual
fragment screening strategy followed by structure-based li-
gand design.
We wish to emphasize three results from this study: (1)
Virtual fragment screening was successfully applied to dis-
cover two novel PTR1 inhibitor scaffolds. (2) X-ray crystal-
lography could confirm the binding mode of one of the
inhibitors,butunexpectedbindingmodeswerealsoobserved.
(3) A highly selective and potent TbPTR1 inhibitor was
designed that can now serve as a chemical tool for target
validation.
Ourvirtualfragmentdockingprotocolidentifiedtwonovel
PTR1 inhibitor scaffolds (Table 1). There is an ongoing
debate in the field whether ligand-based or protein-based
methods are more effective in virtual screening.
24-27 The
scaffolds discovered in this study have a low Tanimoto
similarity (e0.5) to previously known PTR1 and DHFR
inhibitor scaffolds, suggesting that a purely ligand-based
screening approach based on 2D similarity would not have
been able to identify these compounds.
Fragment docking has been reported for a variety of
targets.
17 However, it was noted that the scoring functions
that were originally developed for drug-like ligands do not
perform equally well for fragment-like ligands.
17 As previous
studies demonstrated that pharmacophore constraints are
useful tools to overcome these limitations,
28,29 we adopted
this strategy and filtered the docking poses using interaction
fingerprints.
30 As hypothesized, a better ranking for the
putative ligands was achieved (Table 1). However, at least
one representative per chemical series ranked already among
the top 100 best scoring compounds before reranking. Argu-
ably, in this study, pharmacophore constraints facilitated
visualinspectionbutevenwithoutfiltering,thesamescaffolds
would have been discovered.
Knowledge of the binding mode of a fragment is crucial to
accelerate optimization of binding affinity.
17,18 One of the
binding modes of fragment 4 was correctly predicted by our
docking protocol (Figure 4). However, crystal structure ana-
lysis revealed thatdifferenttautomericforms of this fragment
adopt two distinct binding modes. The second tautomer was
present in our database and was predicted to bind in the
conformation found in the crystal structure, but because only
thehighestscoringversionofeachligandwassavedinthefinal
hitlist,thisbindingmodewasnotconsideredwheninspecting
the virtual screening hits. Removal of the chlorine atom of
4 resulted in ligand 5, which adopts a further distinct binding
mode (Figure 5). In this orientation, two water molecules
mediate contacts between the ligand and the protein. Finally,
when 4 was substituted on N1 with a dichlorobenzyl moiety
(9), the protein pocket expanded slightly and the ligand no
longerformedhydrogenbondswiththecofactorbutboundat
a distal site interacting with Asp161 (Figure 6). None of these
binding modes was predicted correctly. This points to well
recognized issues with molecular docking, which are not
specific tofragment docking, such as treatment of tautomeric
states, structural water molecules, and protein flexibility.
31
Progresshasbeenmadeespeciallyinaddressingthelattertwo
areas. However, more work remains to be done before these
methodscanberoutinelyemployedinmoleculardocking.
32,33
The different binding modes for the aminobenzimidazole
derivatives4,5,an d9(Figure7)arealsointerestingregarding
ongoing discussions on if, or how, the binding modes of the
ligands changewhen going from fragmenttoleadand drug.
17
BabaogluandShoichetdeconstructedaβ-lactamaseinhibitor
into four fragments and found different binding modes for
each of them.
34 However, only one of these fragments con-
tainedthe same key recognition element thatwas also present
Figure 9. Crystallographically determined binding mode of 12
together with Fo-Fc omit map (contoured on 2.0σ), which was
calculated by omitting the ligand from the final model. The phenyl
group of the ligand forms an edge-face interaction with Trp221.Article Journal of Medicinal Chemistry, 2009, Vol. 52, No. 14 4461
in the parent molecule. This might potentially explain the
multiple observed binding modes in their case.
35 Here, all
three ligands contain the same key recognition element, the
benzimidazole motive, but due to the substitution patterns
of 5 and 9, their binding modes are mutually exclusive.
A substituent in N1-position in the binding orientation of 5
would lead to a steric clash with the phosphate group of the
cofactor (Figure 4), while substituting the 8-position in the
binding mode of 9 would lead to a steric clash with Phe174
(Figure 6). The smaller fragment 4 could theoretically adopt
either of these binding modes. Instead, the ligand binds in a
third orientation with water-mediated contacts to the phos-
phategroupofthecofactorandanedge-faceinteractionwith
the aromatic side chain of Trp221. The later interaction has
been observed to be important to improve binding affinity of
unrelatedPTR1inhibitors(unpublishedresults)andmightbe
the driving force for this orientation.
ChemicalvalidationofTbPTR1asadrugtargetforHATis
still outstanding. To this end, potent and selective PTR1
inhibitors are needed. Here, we focused on optimizing one
of the two scaffolds that were discovered by virtual fragment
screening. Out of the three possible binding modes that the
aminobenzimidazole derivatives can adopt in the binding
pocket, we chose the binding mode of 9 as a start point for
hit expansion. Because of pronounced differences between
DHFR and PTR1 in the area of the active site where this
inhibitor binds, this strategy should lead to highly selective
PTR1 inhibitors.
To optimize the submicromolar activity of 9 (Table 2),
we sought to fill the hydrophobic pocket close to Trp221
identified by the analysis of the crystal structure TbPTR139
(Figure 8). Indeed, the subsequently synthesized phenyl-deri-
vative 12 was more than 100-fold more active than 9 and
highly selective over both human and T. brucei DHFR. Its
measured logD is with 3.7 units in a range that suggests that
this compound should be membrane permeable. In addition,
this ligand has a PSA of only 55 A ˚ 2, which is well in the
required range for compounds to pass the blood-brain
barrier, a property required to treat the second stage of
African sleeping sickness.
2,3,14 Consequently, the ligand
should be a valuable tool to support chemical validation of
TbPTR1 as drug target. Somewhat surprisingly, this ligand
poorly inhibited T. brucei cell growth in culture, having an
EC50 value of only 10 μM. Similar results have been obtained
with PTR1 inhibitors containing different chemical scaffolds
(unpublished data). At the moment, it is unclear what the
reasons are for lack of translation of potent inhibition of
PTR1 to an antiproliferative activity against the parasites in
culture. Studies are underway to investigate this further.
Methods
Preparation of Small Molecule Databases. An in-house data-
base containing over 2.2 million commercially available com-
pounds was constructed and associated physicochemical
descriptors along with flags for unwanted groups were calcu-
latedasdescribedpreviously.
19Formoleculardocking,inhouse
python scripts basedon OpenEye’s OEToolkit (Openeye, Santa
Fe, NM) were used to generate common tautomeric states and
to charge small molecules, whereas for acidic and basic groups
withestimatedpKavalues between5and9both,theneutraland
charged forms were stored. Three dimensional conformations
were calculated using Corina (Molecular Networks, Germany),
and low energy conformers were sampled using Omega (Open-
eye). Partial atomic charges and desolvation energies for the
transfer from high-dielectric media (simulated as water) to low
dielectric media (simulated as cyclohexane) were computed
using AMSOL (http://comp.chem.umn.edu/amsol/) with the
same settings as used previously.
36 The generated molecules
were stored in ahierarchical whereas eachring fragment ofeach
database molecule was sequentially used as anchor to align the
conformers resulting in several anchors for molecules contain-
ing multiple ring fragments.
20
Receptor Preparation. The crystal structure of TbPTR1 in
complex with triamterene and NADP
+ (PDB code 3BME) was
chosenasthereceptorforthisstudy.Polarhydrogenatomswere
added and their positions were minimized using the MAB force
field
37,38 as implemented in Moloc (Gerber Molecular Design,
Switzerland) with the ligand present in order to obtain a hydro-
gen-bonding network optimized for ligand binding. Subse-
quently, all crystallographic water molecules and the inhibitor
were removed. Amber charges were assigned to the protein
atoms and AMSOL charges to the cofactor. Spheres were
manuallyplacedinthebindingsiteintheareathatwasoccupied
by the pyrido[3,4-b]pyrazine-2,5,7-triamine part of the ligand
and used as receptor matching positions for docking and to
lower the effective dielectric in the bindings. Grids to store
information about excluded volumes, electrostatic and van der
Waals potential, and solvent occlusion were calculated as
described earlier.
36
Molecular Docking. DOCK 3.5.54 was used to dock small
molecules flexibly in to the active site of TbPTR1.
20,21 The fol-
lowing settings were chosen to sample ligand orientations:
ligand and receptor bins were set to 0.5 A ˚ , overlap bins were
set to 0.4 A ˚ , the distance tolerance for matching ligand atoms to
receptor matching sites ranged from 1.1 to 1.2 A ˚ . Each docking
pose which did not place any atoms in areas occupied by
the receptor was scored for electrostatic and van der Waals
complementarity
20 and penalized according to its estimated
partial desolvation energy (B. Shoichet, unpublished). For each
compound, only the best-scoring database representation (tau-
tomer, protonation state, multiple ring alignment) was stored in
the final docking hit list.
Pharmacophore-Based Filtering of Docking Poses and Visual
Inspection. After analysis of available crystal structures, key
interactions in the pteridine binding site were identified as
π-stacking interactions to Phe97 and the nicotinamide part of
the cofactor NADP
+, an essential hydrogen bond to one of the
oxygen atoms of the phosphate group of the cofactor, and
optional hydrogen bonds to either the hydroxyl group of
Ser95, Tyr174, or the ribose part of the cofactor (Figure 2). To
filter and cluster the docking poses, the hydrogen bond interac-
tions identified were encoded into interaction fingerprints.
30
A hydrogen bond interaction was assumed when a distance of
<3.5 A ˚ was measured between the protein atoms potentially
involved in hydrogen bonds described above and a heteroatom
of the ligand. Compounds passing this filter step were mini-
mized in the binding site using the MAB force field
32,33 as
implemented in Moloc. Subsequently, the obtained binding
poses were visually inspected and representative compounds
still maintaining the required hydrogen-bond network were
short-listed for purchase.
Structure-Based Ligand Design. Starting with the crystal
structure of TbPTR139, potential derivatives of the hit com-
pound that bear moieties suitable to fill the hydrophobic pocket
next to Trp221 (Figure 8) were constructed using Moloc. Sub-
sequently their binding modes were minimized using the MAB
forcefieldandpromisingcompoundswereselectedforsynthesis
Calculation of Tanimoto Coefficients and Polar Surface Area.
Tanimoto coefficients were calculated using Sybyl (Tripos, St.
Louis, MO) based on standard Tripos fingerprints. Topological
polar surface areas were calculated using a Python script pro-
vided by Openeye based on a previously published method.
39
PTR1 and DHFR Activity Assays. Compounds 2-4 and 8-9
were purchased from Asinex, compound5 from Sigma-Aldrich,4462 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 14 Mpamhanga et al.
andcompound7fromChemdiv.Purity(>90%)andidentityof
these compounds was confirmed by LCMS. Compound 6 was
available in-house from a different chemistry program and its
synthesis will be reported elsewhere. The synthesis for com-
pounds 10-12 is reported below.
TbPTR1 and DHFR activity was measured in 96-well micro-
titer plates via reduction of cytochrome c (cytc) as a result of the
enzymatic production of tetrahydrobiopterin (H4B) and tera-
hydrofolate (H4F), respectively. In brief, TbPTR1 activity was
assayed in a buffer containing 20 mM sodium citrate, 1 mM
EDTA, H2B (0.35μM),cytc (81μM), andNADPH (100μM) at
pH 6.0; DHFR was assayed in 20 mM sodium citrate, 1 mM
EDTA, H2F (4.4 μM), cytc (81 μM), and NADPH (100 μM) at
pH 7.4. Enzyme activity was monitored by reading absorbance
at 550 nm within the linear phase of reaction. Full details of this
method will be reported in a separate publication. Ki
app values
were calculated using a modified Morrison equation.
40
Protein Crystallization, Data Collection, and Structure Solu-
tion. TbPTR1 was purified and crystallized as described pre-
viously.
15 In short, TbPTR1 was concentrated to 6 mg/mL in
20 mM Tris-HCl pH 8.0. Ligands were solubilized to a concen-
tration of 200 mM in DMSO. The ternary complex of TbPTR1
withcofactorandligandwaspreparedbyincubatingtheprotein
solution (6 mg/mL) with 2 mM of the ligand, 1 mM NADP
+,
and 20 mM dithiothreitol in 20 mM Tris-HCl pH 8.0 on ice for
30 min prior to crystallization. Crystallization was carried out
by the vapor diffusion method by mixing 2 μL of the protein
solution with 2 μL of the reservoir solution and incubating the
drops over 100 μL of the reservoir in sitting drop plates. The
reservoir solution consisted of 1.5-3.0 M sodium acetate and
0.1 M citrate buffer pH 4.5-6.0. Diffraction quality crystals
were obtained after 2-3 days at 18  C.
Diffraction data for the complexes with 4, 5, and 12 were
measured using a rotating anode X-ray source (Rigaku Micro-
max 007) and an image plate detector (Rigaku R-AXIS IV
+ +)
and for the remaining complex at beamline ID23-1 at the
EuropeanSynchrotronRadiationFacility(ESRF)inGrenoble,
France. Crystals were prepared for data collection by transfer-
ring them through a cryoprotection solution of mother liquor
with 20% glycerol added and then flash frozen in a stream of
gaseous nitrogen at -173  C. Data were integrated and scaled
using MOSFLM
41 and SCALA
42 from the CCP4
43 suite of
programs, except for complex PTR1312, for which the HKL
suite was used.
44
Molecular replacement as implemented in MOLREP
45 was
used to solve the structure using the protein chains from
the TbPTR13methotrexate complex
15 (PDB 2C7V) as the start-
ing model. After the molecular replacement step, a round of
rigid-body refinement was carried out using REFMAC5.
46,47
Ligand models and associated topology files were created with
PRODRG
48 and were built into Fo-Fc electron density maps
using COOT.
49 Further rounds of restrained refinement were
carried out using REFMAC5 and manual alteration of the
models, including addition of solvent molecules using COOT.
Figures of protein-ligand complexes were produced using
PyMOL (DeLano Scientific, Palo Alto, CA).
Synthesis of Amino-benzimidazole Analogues.
1H NMR spec-
tra were recorded on either a Bruker Avance DPX 500 or on a
Bruker Avance 300 spectrometer. Chemical shifts (δ) are ex-
pressed in ppm. Signal splitting patterns are described as singlet
(s), broad singlet (bs), doublet (d), triplet (t), quartet (q), multi-
plet (m), or combinations thereof.
Low resolution electrospray (ES) mass spectra were recorded
on a Bruker MicroTof mass spectrometer, run in positive ion
mode, using either methanol, methanol/water (95:5), or water/
acetonitrile (1:1) and 0.1% formic acid as the mobile phase.
High resolution electrospray measurements were performed on
a Bruker MicroTof mass spectrometer.
LC-MS analysis and chromatographic separations were con-
ducted with a Bruker MicroTof mass spectrometer using an
Agilent HPLC 1100 with a diode array detector in series. The
column usedwas aPhenomenex GeminiC18column, 50 mm 3.0
mm, 5 mm particle size. The following method was used: mobile
phase, water/acetonitrile +0.1% HCOOH 80:20 to 5:95 gradient
over 3.5 min, and then held at for 1.5 min; flow rate 0.5 mL/min.
All compounds exemplified had a measured purity of greater
than 95% on this analytical HPLC-MS system (TIC and HPLC
UV). HPLC retention times and M
+ data are given below to
substantiate the purity and integrity of the compounds.
1H
NMR also confirmed compound identity and purity (wrt other
organic components being absent).
Thin layer chromatography (TLC) was carried out on Merck
silica gel 60 F254 plates using UV light and/or KMnO4 for
visualization. TLC data are given as the Rf value with the
corresponding eluent system specified in brackets. Column
chromatography was performed using RediSep 4 or 12 g silica
prepacked columns.
All reactions were carried out under dry and inert conditions
unless otherwise stated.
7-Chloro-1-(3,4-dichlorobenzyl)-1H-benzo[d]imidazol-2-amine (10).
7-Chloro-1H-benzo[d]imidazol-2-amine(16)(200mg,1.19mmol),
potassium hydroxide flakes (100 mg, 1.79 mmol), and 3,4-dichlor-
obenzyl chloride (244 mg, 1.25 mmol) were stirred in 15 mL
ethanol at 20  C for 48 h. The solution was then concentrated by
removing the ethanol and diluted with 40 mL ethyl acetate and
washed with sodium bicarbonate solution (120 mL), water (1
30 mL), and brine (220 mL). The organic layer was dried with
magnesiumsulfateandconcentratedtoremovetheethylacetateto
afford a cream-colored solid. Compound 10 was the more polar
product obtained purified by flash column chromatography (10%
methanol/ dichloromethane eluent), yielding compound 10 as a
white solid (68 mg, 17% yield).
1HN M Ra n dL C M Sc o n f i r m e d
purity at >98%.
The relative
1H NMR signal for the CH2-dichlorobenzyl
protons at 5.54 ppm, versus 5.28 ppm for 4-isomer, agrees with
the expected shift for a 7-substituted N
1-benzylated benzimida-
zole versus a 4-substituted benzimidazole.
50
1H NMR (500 MHz, DMSO): δ=5.54 (2H, s, CH2), 6.78 (2H, s,
NH2),6.83(1H,m,ArH),6.95(1H,dd(J=2.1 Hz, J=8.4 Hz) ArH),
6.97 (1H, t (J=7.9 Hz) ArH), 7.15 (1H, dd (J=0.9Hz,J=7.8Hz),
A r H ) ,7 . 3 1( 1 H ,s ,A r H ) ,7 . 6 1( 1 H ,d( J=8.3 Hz), ArH).
LCMS (ES
+): m/z (%) 327 (M+H)
+, retention time 0.9 min.
HRMS (ES
+): calcd for (Cl35) C14H11Cl3N3 [M+H]
+
326.0013, found 325.9998 (4.47 ppm).
7-(n-Propyloxy)-1-(3,4-dichlorobenzyl)-1H-benzo[d]imidazol-
2-amine (11). 7-(n-Propyloxy)-1H-benzo[d]imidazol-2-amine (13)
(250 mg, 1.31 mmol), potassium hydroxide flakes (110 mg,
6.28mmol),and3,4-dichlorobenzylchloride(269mg,1.38mmol)
were stirred in 10 mL ethanol at 20  C for 48 h. The reaction
was worked up as described for compound 10, and columned.
Compound 11 was the more polar product obtained purified by
flash column chromatography (10% methanol/ dichloromethane
eluent),yieldingcompound11asawhitesolid(90mg,20%yield).
1HN M Ra n dL C M Sc o n f i r m e dp u r i t ya t> 9 8 % .
Absolute regiochemistry of compound 11 was confirmed by
therelative
1HNMRsignalfortheCH2-dichlorobenzylprotons
at 5.48 ppm, versus 5.08 ppm for 4-isomer. This agrees with the
expected shift for a 7-alkoxy substituted N
1-benzylated benzi-
midazole versus a 4-substituted benzimidazole.
50
1HNMR(300 MHz,CDCl3):δ=0.94(3H,t(J=7.4 Hz), CH3),
1.71 (2H, m, CH2), 4.03 (2H, t (J=6.4 Hz), CH2), 4.30 (2H, bs,
NH2),5.48(2H,s,CH2),6.62(1H,dd(J=1.1 Hz, J=7.7Hz),ArH),
7.08(2H,m,2ArH),7.13(1H,m,ArH),7.35(1H,s,ArH),7.42(1H,
d( J=8.3 Hz), ArH).
LCMS (ES
+): m/z (%) 351 (M+H)
+, retention time 0.9 min.
HRMS (ES
+): calcd for C17H18Cl2N3O [M+H]
+ 350.0821,
found 350.0815 (1.75 ppm).
7-Phenyl-1-(3,4-dichlorobenzyl)-1H-benzo[d]imidazol-2-amine (12).
7-Phenyl-1H-benzo[d]imidazol-2-amine(18)(115mg,0.55mmol),
potassium hydroxide flakes (46 mg, 0.83 mmol), and 3,4-dichlor-Article Journal of Medicinal Chemistry, 2009, Vol. 52, No. 14 4463
obenzyl chloride (113 mg, 0.58 mmol) were stirred in 8 mL of
ethanol at 20  C for 48 h. The reaction was worked up described
for compound 10 and columned. Compound 12 was the more
polarproductobtainedpurifiedbyflashcolumnchromatography
(10% methanol/dichloromethane eluent), collected as a white
solid (35 mg, 18% yield).
1H NMR and LCMS confirmed purity
at >98%.
Absolute regiochemistry of compound 12 was confirmed by
NOESY NMR: a strong interaction between CH2-dichloroben-
zyl protons at 4.88 ppm (2H, s, CH2) and the ortho proton
signals of the pendant phenyl ring at 7.12 ppm (2H, d, CH) was
observed, indicating close proximity of these substituents. Also
a crystal structure of compound 12 complex with PTR1 enzyme
wasobtained(Figure9),confirmingtheabsoluteregiochemistry
of compound 12 as 7-phenyl-1-(3,4-dichloro)-1H-benzo(d)imi-
dazol-2-amine.
1HNMR(500MHz,DMSO):δ= 4.88(2H,s,CH2),6.37(1H,dd
(J=2.1 Hz, J=8.3Hz),ArH),6.50(1H,m,ArH),6.60(2H,s,NH2),
6.61 (1H, dd (J=1.1 Hz, J=7.5 Hz), ArH), 7.00 (1H, t (J=7.7 Hz),
A rH ) ,7 . 1 2( 2H ,b d( J=8.3 Hz),ArH), 7.21 (1H, dd(J=1.1 Hz, J=
7.8 Hz), ArH), 7.31 (2H, t (J=7.3 Hz), 2ArH), 7.38 (2H, m, 2ArH).
LCMS (ES
+): m/z (%) 369 (M+H)
+, retention time 0.9 min.
HRMS (ES
+): calcd for C20H16Cl2N3 [M+H]
+ 368.0716, fo-
und 368.0708 (2.05 ppm).
7-(n-Propyloxy)-1H-benzo[d]imidazol-2-amine (13). 3-n-Pro-
pyloxybenzene-1,2-diamine (14) (410 mg, 2.47 mmol) and cya-
nogenbromide2Msolutioninacetonitrile(1.36mL,2.72mmol)
werestirredinacetonitrile(12mL)andwater(3mL)at20 Cfor
36 h. The mixture was then concentrated to remove the acet-
onitrile. Ethyl acetate (40mL)andsodium bicarbonatesolution
(140 mL) were added, and the biphasic solution was trans-
ferredtoaseparatingfunnel.Theorganiclayerwaswashedwith
water (125 mL), sodium bicarbonate solution (120 mL), and
brine (230 mL), before being dried with MgSO4 and concen-
tratedtoremoveethylacetate.Crudecompound13waspurified
by flash column chromatography (8% methanol/dichloromethane
eluent),yieldingcompound13asawhitesolid(300mg,64%yield).
1H NMR and LCMS confirmed purity at >98%.
1H NMR (500 MHz, CDCl3): δ=1.01 (3H, t (J=7.4 Hz),
CH3),1.72(2H,m,CH2),4.03(2H,m,CH2),5.83(2H,bs,NH2),
6.46 (1H, m, ArH), 6.86 (2H, m, ArCH), 10.70 (1H, bs, NH).
LCMS (ES
+): m/z (%) 192 (M+H)
+, retention time 0.6 min.
3-Propoxybenzene-1,2-diamine(14).2-Nitro-6-propoxyaniline
(15) (300 mg, 1.53 mmol) and tin(II) chloride (1.45 g, 7.65 mmol)
were taken into in ethanol (15 mL). The reaction was heated in a
microwave reactor at 140  C for 10 min and then poured into
NaHCO3 solution (30 mL) and the product was extracted into
ethyl acetate (225 mL). The organic layers were combined and
washed with sodium bicarbonatesolution (130 mL), water (1
30mL),andbrine(240mL)beforebeingdriedwithMgSO4and
concentrated to remove ethyl acetate. The solution was concen-
trated to remove ethyl acetate, affording compound 14 as a pale-
yellow gum in quantitative yield.
1HN M Ra n dL C M Sc o n f i rm e d
purity at >95%.
1H NMR (500 MHz, CDCl3): δ=1.07 (3H, t (J=7.4 Hz), CH3),
1.82(2H,m,CH2),3.44(2H,m,NH2),3.98(2H,t(J=6.5 Hz), CH2),
6.40 (2H, m, ArH), 6.68 (1H, t (J=8.0 Hz), ArH).
LCMS (ES
+): m/z (%) 167 (M+H)
+, retention time 0.5 min.
2-Nitro-6-propoxyaniline(15).2-Amino-3-nitrophenol(500mg,
3.23 mmol), K2CO3 (669 mg, 4.84 mmol), and 3-bromopropane
(438mg,3.35mmol)weretakenintoDMF(35mL).Thereaction
was stirred at 20  C for 12 h and then poured into NaHCO3
solution(20mL),andtheproductwasextractedintoethylacetate
(230 mL). The organic layers were combined then washed with
water (130 mL), sodium bicarbonate solution (130 mL), and
brine(240mL)beforebeingdriedwithMgSO4andconcentrated
toremoveethylacetate.Crudecompound15waspurifiedbyflash
column chromatography (3% methanol/dichloromethane elu-
ent), affording compound 15 as a pale-yellow solid (460 mg,
73% yield).
1H NMR and LCMS confirmed purity at >98%.
1HNMR(500MHz,CDCl3):δ=1.09(3H,s,CH3),1.91(2H,
s,CH2),4.02(2H,m,CH2),6.47(2H,m,NH2),6.64(1H,dd(J=
7.8 Hz, J=8.9 Hz), ArH), 6.91 (1H, d (J=7.6 Hz), ArH), 7.75
(1H, dd (J=1.1 Hz, J=8.9 Hz), ArH).
LCMS (ES
+): m/z (%) 197 (M+H)
+, retention time 0.5 min.
7-Chloro-1H-benzo[d]imidazol-2-amine (16). Prepared like
compound 13, starting from 3-chlorobenzene-1,2-diamine (17)
(624 mg, 4.38 mmol) and cyanogenbromide 2 M solution in
acetonitrile (2.41 mL, 4.82 mmol), in acetonitrile (18 mL), and
water (4 mL). The reaction was stirred at 20  C for 36 h. Crude
compound 16 was purified by flash column chromatography
(8% methanol/dichloromethane eluent), yielding compound 16
as a white solid (510 mg, 69% yield).
1H NMR and LCMS
confirmed purity at >98%.
1H NMR (500 MHz, CDCl3): δ=6.40 (2H, bs, NH2), 6.79
(1H,bm,ArH),6.90(1H,m,ArH),7.0(1H,dd(J=0.8Hz,J=
7.8 Hz), ArH), 10.94 (1H, bs, NH).
LCMS(ES
+): m/z(%)168.5(M+H)
+,retentiontime0.6min.
3-Chlorobenzene-1,2-diamine (17). Prepared like compound
14, using 2-chloro-6-nitroaniline (1.0 g, 5.8 mmol), tin(II)
chloride (5.5 g, 29 mmol) in ethanol 30 mL). Compound 17
was obtained in quantitative yield as a colorless gum. LCMS
confirmed purity at >95%. Used as “crude” in example 16.
LCMS (ES
+): m/z (%) 143 (M+H)
+, retention time 0.4 min.
7-Phenyl-1H-benzo[d]imidazol-2-amine (18). Prepared like
compound 13, starting from biphenyl-2,3-diamine (19) (350 mg,
1.9 mmol) and cyanogenbromide 2 M solution in acetonitrile
(1.05 mL, 2.09 mmol), in acetonitrile (18 mL), and water (4 mL).
The reaction was stirred at 20  C for 18 h and worked up as
described above. Crude compound 18 was purified by flash
column chromatography (8% methanol/dichloromethane elu-
ent), yielding compound 18 as a white solid (250 mg, 63% yield).
1HN M Ra n dL C M Sc o n f i r m e dp u r i t ya t> 9 8 % .
1HNMR(500MHz,DMSO):δ= 6.22(2 H,s,CH 2),6.95(1H,t
(J=7.7 Hz), ArH), 7.08 (1H, m, ArH), 7.31 (1H, t, (J=7.5 Hz),
ArH), 7.44 (1H, t (J=7.6 Hz), ArH), 7.90 (2H, bs, NH2), 10.90
(1H, bs, NH).
LCMS (ES
+): m/z (%) 210 (M+H)
+, retention time 0.5 min.
Biphenyl-2,3-diamine (19). Prepared like compound 14, using
3-phenyl-2-nitroaniline (20) (500 mg, 2.34 mmol), tin(II) chlor-
ide (2.2 g, 11.7 mmol) in ethanol 25 mL). The reaction was
heated in a microwave reactor at 140  C for 10 min and then
worked up as previously described. The solution was concen-
trated to remove ethyl acetate, affording compound 19 in
quantitative yield, as a colorless gum. LCMS confirmed purity
at >95%. Used as “crude” in example 18.
LCMS (ES
+): m/z (%) 184 (M+H)
+, retention time 0.5 min.
3-Phenyl-2-nitroaniline (20). A solution of 2-phenylnitroben-
zene (398 mg, 2 mmol) and o-methylhydroxylamine (118 mg,
2.5 mmol) in DMF (3 mL) was added dropwise (over 5 min) to a
stirredsuspensionof
tBuOK(672mg,6mmol)andCu(I)Cl(20mg,
0.2 mmol) in DMF (7 mL). The reaction was stirred at 20  Cf o r
60 min and then quenched with ammonium chloride solution. The
product was extracted into DCM, dried with MgSO4, and con-
centrated to remove the dichloromethane. Compound 20 was
separated from the side product (2-phenyl-4-nitroaniline) and
remaining starting material by flash column chromatography
(10% ethyl acetate/hexane eluent), affording compound 20 as a
yellow solid (86 mg, 20% yield).
1HN M Ra n dL C M Sc o n f i r m e d
purity at >98%.
1HNMR(500MHz,CDCl3):δ=6.5 (1H, dd (J=1.3 Hz, J=7.7
Hz),ArH),6.57(2H,s,NH2),6.8(1H,m,ArH),6.89(1H,d(J=7.7
H z ) ,A r H ) ,6 . 9 5( 1 H ,d t( J=1.2 Hz, J= 7.6 Hz), ArH), 7.2 (2H, m,
2ArH), 7.3 (1H, dt (J=1.6 Hz, J=7.7 Hz), ArH), 7.53 (1H, dd
(J=1.1 Hz, J=7.9 Hz), ArH).
LCMS (ES
+): m/z (%) 215 (M+H)
+, retention time 0.6 min.
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